sarcosine has been researched along with Disease Exacerbation in 9 studies
cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis
| Excerpt | Relevance | Reference |
|---|---|---|
| "The severity of tau pathology in Alzheimer's disease brain correlates closely with disease progression." | 1.40 | Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. ( Bohrmann, B; Collin, L; Göpfert, U; Grüninger, F; Oroszlan-Szovik, K; Ozmen, L, 2014) |
| "Metabolomic profiling of prostate cancer (PCa) progression identified markedly elevated levels of sarcosine (N-methyl glycine) in metastatic PCa and modest but significant elevation of the metabolite in PCa urine." | 1.39 | The role of sarcosine metabolism in prostate cancer progression. ( Asangani, IA; Ateeq, B; Athanikar, JN; Chinnaiyan, AM; Khan, AP; Mehra, R; Michailidis, G; Palapattu, G; Rajendiran, TM; Siddiqui, J; Sreekumar, A; Wei, JT; Yocum, AK, 2013) |
| "Sarcosine is reported to be a differential metabolite that is greatly increased during prostate cancer (PCa) progression." | 1.38 | Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. ( Battaglia, M; Bettocchi, C; Ditonno, P; Fanelli, M; Germinario, CA; Larocca, AM; Lucarelli, G; Rutigliano, M; Selvaggi, FP; Vavallo, A, 2012) |
| "Sarcosine values were not associated with tumor stage (pT2 vs pT3), tumor grade (Gleason score less than 7 vs 7 or greater) or biochemical recurrence." | 1.37 | Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. ( Bethan, B; Jentzmik, F; Jung, K; Kamlage, B; Kristiansen, G; Lein, M; Miller, K; Stephan, C, 2011) |
| "Sarcosine levels were also increased in invasive prostate cancer cell lines relative to benign prostate epithelial cells." | 1.35 | Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. ( Ahsan, A; Alexander, DC; Beecher, C; Berger, A; Byun, J; Cao, Q; Cao, X; Chinnaiyan, AM; Ghosh, D; Han, B; Kalyana-Sundaram, S; Khan, AP; Laxman, B; Li, Y; Lonigro, RJ; Mehra, R; Nyati, MK; Omenn, GS; Pennathur, S; Poisson, LM; Rajendiran, TM; Shuster, JR; Sreekumar, A; Varambally, S; Wei, JT; Yu, J, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Khan, AP | 2 |
| Rajendiran, TM | 2 |
| Ateeq, B | 1 |
| Asangani, IA | 1 |
| Athanikar, JN | 1 |
| Yocum, AK | 1 |
| Mehra, R | 2 |
| Siddiqui, J | 1 |
| Palapattu, G | 1 |
| Wei, JT | 2 |
| Michailidis, G | 1 |
| Sreekumar, A | 2 |
| Chinnaiyan, AM | 2 |
| Heger, Z | 1 |
| Cernei, N | 1 |
| Gumulec, J | 1 |
| Masarik, M | 1 |
| Eckschlager, T | 1 |
| Hrabec, R | 1 |
| Zitka, O | 1 |
| Adam, V | 1 |
| Kizek, R | 1 |
| Collin, L | 1 |
| Bohrmann, B | 1 |
| Göpfert, U | 1 |
| Oroszlan-Szovik, K | 1 |
| Ozmen, L | 1 |
| Grüninger, F | 1 |
| Poisson, LM | 1 |
| Cao, Q | 1 |
| Yu, J | 1 |
| Laxman, B | 1 |
| Lonigro, RJ | 1 |
| Li, Y | 1 |
| Nyati, MK | 1 |
| Ahsan, A | 1 |
| Kalyana-Sundaram, S | 1 |
| Han, B | 1 |
| Cao, X | 1 |
| Byun, J | 1 |
| Omenn, GS | 1 |
| Ghosh, D | 1 |
| Pennathur, S | 1 |
| Alexander, DC | 1 |
| Berger, A | 1 |
| Shuster, JR | 1 |
| Varambally, S | 1 |
| Beecher, C | 1 |
| Darbon, JM | 1 |
| Zilka, N | 1 |
| Korenova, M | 1 |
| Kovacech, B | 1 |
| Iqbal, K | 1 |
| Novak, M | 1 |
| Jentzmik, F | 1 |
| Stephan, C | 1 |
| Lein, M | 1 |
| Miller, K | 1 |
| Kamlage, B | 1 |
| Bethan, B | 1 |
| Kristiansen, G | 1 |
| Jung, K | 1 |
| Lucarelli, G | 1 |
| Fanelli, M | 1 |
| Larocca, AM | 1 |
| Germinario, CA | 1 |
| Rutigliano, M | 1 |
| Vavallo, A | 1 |
| Selvaggi, FP | 1 |
| Bettocchi, C | 1 |
| Battaglia, M | 1 |
| Ditonno, P | 1 |
| Sahara, N | 1 |
| Lewis, J | 1 |
| DeTure, M | 1 |
| McGowan, E | 1 |
| Dickson, DW | 1 |
| Hutton, M | 1 |
| Yen, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Uncovering the 'ORIGINS' of Diabetes[NCT02226640] | 80 participants (Actual) | Observational | 2010-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 other studies available for sarcosine and Disease Exacerbation
| Article | Year |
|---|---|
The role of sarcosine metabolism in prostate cancer progression.
Topics: Aged; Animals; Biomarkers, Tumor; Case-Control Studies; Cell Line, Tumor; Disease Progression; Gene | 2013 |
Determination of common urine substances as an assay for improving prostate carcinoma diagnostics.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Chromatography, Liquid; Disease Progress | 2014 |
Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antibodies; Antibodies, Monoclonal; Blot | 2014 |
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.
Topics: Androgens; Cell Line; Cell Line, Tumor; Disease Progression; Gene Knockdown Techniques; Glycine N-Me | 2009 |
[Analysis of the metabolome suggests a major potential role of sarcosine in the progression of cancer of the prostate].
Topics: Dimethylglycine Dehydrogenase; Disease Progression; Glycine N-Methyltransferase; Humans; Male; Metab | 2009 |
CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.
Topics: Animals; Brain; Detergents; Disease Models, Animal; Disease Progression; Humans; Longitudinal Studie | 2010 |
Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.
Topics: Aged; Analysis of Variance; Biomarkers, Tumor; Biopsy, Needle; Cohort Studies; Diagnosis, Differenti | 2011 |
Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy; Case-Control Studies; Dis | 2012 |
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.
Topics: Age Factors; Amino Acid Substitution; Animals; Binding Sites; Brain; Brain Chemistry; Detergents; Di | 2002 |